Replies to post #1662 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

>Sepsis has always been a graveyard for pharma development. I wonder if reliance on this program is one of the reasons for GTCB's overall weakness?<

The thinking on how to treat sepsis with DIC has been undergone a radical shift in the past couple of years, and this is why Leo and GTC opted to pursue this indication. Please see the references in #msg-14363831. Regards, Dew

[DewDiligence]

Speaking of sepsis… one of GTC’s competitors was just delayed this morning:

#msg-14499024